Russia halts landmark deal that allowed Ukraine to export grain at time of growing hunger

TAGGED : health

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA庐 (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease

October 22, 2023

JERSEY CITY, N.J.--(BUSINESS WIRE)--Oct 22, 2023--Today, Celltrion USA announced that the U.S. Food and Drug Administration (FDA) has approved ZYMFENTRA 庐 (infliximab-dyyb) for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) and Crohn蘑菇视频 disease (CD) ...

Norway’s 86-year-old king tests positive for COVID-19 and has mild symptoms

October 22, 2023

HELSINKI (AP) 鈥� Norway蘑菇视频 86-year-old <a href="https://apnews.com/article/norway-king-harald-hospital-infection-bb00c1712b9e9e426409a215a189a569">King Harald V,</a> who has been in frail health in the past few years, has tested positive for the coronavirus and has ...

Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial

October 22, 2023

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 22, 2023--Updated results from a subgroup analysis of a first-in-human <a ...

Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial

October 22, 2023

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 22, 2023--Updated results from the <a ...

Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

October 22, 2023

ALAMEDA, Calif.--(BUSINESS WIRE)--Oct 22, 2023--<a ...

Merck蘑菇视频 WELIREG庐 (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

October 21, 2023

RAHWAY, N.J.--(BUSINESS WIRE)--Oct 21, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 LITESPARK-005 trial investigating WELIREG, Merck蘑菇视频 first-in-class, oral hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor, for the ...